Terns Inc. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity and liver diseases.
Evotec International GmbH and Nosopharm SAS have jointly described odilorhabdin analogues reported to be useful for the treatment of multidrug-resistant bacterial infections.
A patent from Nanjing Mingde New Drug Research Co. Ltd. and Zhangzhou Pientzehuang Pharmaceutical Co. Ltd. details the identification of salts of interleukin-1 receptor-associated kinase 4 (IRAK-4) degradation inducers reported to be useful for the treatment of diffuse large B-cell lymphoma.
Work at LG Chem Ltd. has led to the development of novel benzimidazolone derivatives acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors potentially useful for the treatment of cancer and fibrosis.
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. has patented new tricyclic compounds acting as serine/threonine-protein kinase ATR inhibitors and thus reported to be useful for the treatment of colon cancer.
In what represents the first patenting from Cerathrive Ltd., its co-founder and CEO, Sarah Turner, describes their development of the Cera system, which they claim to be the first and only U.S. FDA-cleared red-light device that targets the gut-brain axis to improve focus and energy levels.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Work at Janssen Pharmaceutica NV has led to the identification of lactam-containing imidazopyridazine interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors.
RSS
